# Kōichi Goto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/koichi-goto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,186 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 69 |
| i10-index | 307 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5037461196 |
| ORCID iD | 0000-0002-3023-2510 |
| Works | 935 |

## Researcher papers

Showing 12 of 20.

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies](https://scholariq.org/papers/the-pd-1-expression-balance-between-effector-and-regulatory-t-cells-predicts-the/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/prophylactic-cranial-irradiation-versus-observation-in-patients-with-extensive/)
- [TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer](https://scholariq.org/papers/tatton-a-multi-arm-phase-ib-trial-of-osimertinib-combined-with-selumetinib/)
- [Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial](https://scholariq.org/papers/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.